Zurich Cantonal Bank’s Precision BioSciences DTIL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-69
Closed -$381 2844
2025
Q3
$381 Hold
69
﹤0.01% 2534
2025
Q2
$290 Hold
69
﹤0.01% 2547
2025
Q1
$329 Hold
69
﹤0.01% 2617
2024
Q4
$263 Sell
69
-189
-73% -$1.38K ﹤0.01% 2637
2024
Q3
$2.31K Sell
258
-25
-9% -$241 ﹤0.01% 2638
2024
Q2
$2.75K Sell
283
-70
-20% -$825 ﹤0.01% 2629
2024
Q1
$4.79K Sell
353
-11
-3% -$135 ﹤0.01% 2658
2023
Q4
$3.98K Sell
364
-27
-7% -$291 ﹤0.01% 2683
2023
Q3
$4.01K Sell
391
-31
-7% -$476 ﹤0.01% 2756
2023
Q2
$6.66K Hold
422
﹤0.01% 2756
2023
Q1
$9.55K Hold
422
﹤0.01% 2797
2022
Q4
$15.1K Sell
422
-2
-0.5% -$79 ﹤0.01% 2780
2022
Q3
$17K Sell
424
-6
-1% -$285 ﹤0.01% 2821
2022
Q2
$21K Sell
430
-369
-46% -$21.7K ﹤0.01% 2790
2022
Q1
$74K Sell
799
-153
-16% -$20.8K ﹤0.01% 2405
2021
Q4
$211K Buy
952
+152
+19% +$42.5K ﹤0.01% 2033
2021
Q3
$277K Buy
800
+156
+24% +$52.9K ﹤0.01% 1699
2021
Q2
$242K Buy
644
+33
+5% +$9.91K ﹤0.01% 1686
2021
Q1
$190K Buy
+611
New +$214K ﹤0.01% 1807

Other funds holding DTIL

Zurich Cantonal Bank's DTIL Position: Q4 2025 in Review

Zurich Cantonal Bank sold out of Precision BioSciences (DTIL) in Q4 2025, closing a stake of 69 shares — an estimated $381 sold.

Zurich Cantonal Bank first reported a position in DTIL in Q1 2021 and held it in 19 quarters. The position peaked at $277K in Q3 2021. 69 funds tracked by Wall St. Rank hold DTIL as of Q4 2025.

  • Zurich Cantonal Bank reported no remaining Precision BioSciences position as of Q4 2025 after selling out during the quarter.
  • Zurich Cantonal Bank sold 69 Precision BioSciences shares in Q4 2025, an estimated $381.
  • Zurich Cantonal Bank first reported a position in Precision BioSciences in Q1 2021 and held it in 19 quarters.
  • Zurich Cantonal Bank's Precision BioSciences position peaked at $277K in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Precision BioSciences as of Q4 2025.

Based on Zurich Cantonal Bank's 13F filing for Q4 2025, filed 27 Jan 2026.